Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03312699 · ClinicalTrials.gov registry record · Phase 1
Effects of Aging on Primary and Secondary Vaccine Responses
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03312699: Completed Phase 1 study, sponsored by Stanford University.
NCT03312699 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 54 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03312699, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (\>65 years) subjects whose yearly influenza vaccine responses have been studied extensively since 2007, to gain molecular and cellular mechanistic insights into the impaired vaccine responses in the elderly.
Primary Outcome
HAI titers measured at Days 0 and 28 for influenza.
Interventions
- BIOLOGICAL Fluad
- BIOLOGICAL Fluzone High Dose
- BIOLOGICAL Fluzone® quadrivalent
- BIOLOGICAL Vaqta
- BIOLOGICAL Typhim Vi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
What the finished NCT03312699 record still lists
NCT03312699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 5 interventions - of which Fluad is the first listed.
NCT03312699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03312699 about?
NCT03312699 is a clinical study titled "Effects of Aging on Primary and Secondary Vaccine Responses". The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (\>65 years) subjects whose yearly influenza vaccine responses have been studied extensively since 2007, to gain molecular and cellular mechanistic insights into the ...
What is the current status of trial NCT03312699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2017-09-19. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT03312699?
The interventions under investigation include: Fluad (BIOLOGICAL), Fluzone High Dose (BIOLOGICAL), Fluzone® quadrivalent (BIOLOGICAL), Vaqta (BIOLOGICAL), Typhim Vi (BIOLOGICAL).
Who is sponsoring clinical trial NCT03312699?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03312699's enrollment target sits among peer trials
54 931st of 2000 higher than 1,053 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI